What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

A prostate cancer study that could change how doctors treat some patients found that widely used hormone-blocking drugs did not improve survival chances for older men whose disease hadn't spread. In ...

Drug Used for Enlarged Prostate Tied to High Glaucoma Risk The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study ...

What Is Akeega, and Why Does It Matter? Akeega is a dual-action tablet combining two medicines — niraparib and abiraterone acetate — that has been approved by the FDA in combination with prednisone (a ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

A prescription medication that has been available in the U.S. since 1992 might have another significant benefit.

Though most men would rather do just about anything besides talk about their prostate health—including seeing their favorite team lose—by the age of 60, half of men will have developed an enlarged ...